02.- 03.03.2018  


The event SALZBURG BREAST CANCER TALK, MASTERING TRANSLATIONAL IMMUNO-ONCOLOGY from 02. to 03.03.2018, in the PITTER Event Center Salzburg was again a complete success with over 90 participants. The lecturers, including many internationally renowned scientists, were able to providea the expert audience with impressive insights into their research at the pulse of time and also left enough room for interaction. The lively participation of the audience in the discussions proved this emphatically.

The second successful edition of this event confirmed our intention to create a platform in breast cancer immunotherapy and research that will enable rapid and efficient translation of preclinical research into clinical development. In order to implement this in a sustainable manner, a repeat of the event is planned for next year, which is intended to take this symposium, which is currently unique in Europe, to the next level.

The extremely positive feedback from the speakers and the audience about the program composition and the implementation of the event confirm that the organization was once again successful. We would also like to thank the team of the PITTER Event Center, which has always made every effort to ensure that everything runs smoothly.

We would like to take this opportunity to thank all the speakers for coming and all the participants for their numerous attendance. We would like to thank AstraZeneca, Roche, Merck Sharp & Dohme, Pfizer, Bristol Myers-Squibb and Novartis for their financial support, without which this event would not have been possible.
As soon as a date for the Salzburg Breast Cancer Talk 2019 is set, we will announce it.

For all participants and interested parties we put video recordings of some lectures and comments on the event below.

v.l. Prof. Dr. Alberto Mantovani1, Doz. Dr. Alexander Egle2, Dr. Karen Willard-Gallo3, Dr. Gabriel Rinnerthaler2, Dr. Simon Gampenrieder2, Prof. Dr. Richard Greil2, Prof. Dr. Peter Schmid4, Prof. Dr. Fabrice André5

1 Humanitas University, Istituto Clinico Humanitas IRCCS, Milan, Italy
2 IIIrd Medical Department, University Hospital Salzburg, Paracelsus Medical University, Salzburg Cancer Research Institute (SCRI), Cancer Cluster Salzburg (CCS), Salzburg, Austria
3 Molecular Immunology Laboratory, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium
4 Centre for Experimental Cancer Medicine, St Bartholomew Hospital London,London, United Kingdom
5 INSERM, Unit U981, Institut Gustave Roussy, Department of Medical Oncology, Villejuif, France

Foto: Franz Neumayr
Link zur Pressemeldung

Artikel mit Interwiev von Prof. Greil in der Onko News Austria Ausgabe Nr.1-2, April 2018

Webcast courtesy of the speakers:
Prof. Mantovani: The yin yang of innate immunity, inflammation and cancer
Prof. André: Influence on immunogenicity by driver mutations
Dr. Kok: Prediction of response to PD-1/PD-L1 blockade

10. März 2018